Eva Medtec has developed a novel, patented, FDA-approved medical device (The Neuroglide) engineered to naturally reduce pain by removing cellular waste.
By utilizing our innovative technology, individuals can experience safe and effective pain relief without the need for medication or invasive procedures. By naturally alleviating the root cause of chronic pain and inflammation, millions may lead happier, healthier lives.
"There are so many devices out there that claim to improve recovery. None of them are this simple to use."
At Neuroglide, we are passionate about improving people's lives by providing innovative solutions for pain management. Our device was designed by certified lymphatic drainage therapist and inventor, Irene Waldridge, who saw the transformative impact of MLD therapy on her patients' quality of life.
Irene's vision was to make MLD accessible to everyone, which led her to create the Neuroglide, a device that allows individuals to enjoy the benefits of MLD from the comfort of their own homes. Join us in our mission to revolutionize pain management and provide a better quality of life for those who suffer from chronic pain.
EARLY BIRD DISCOUNT
Investors who participate in the offering on or before April 21, 2023 will receive a 20% early bird discount and be able to invest at a purchase price of $1.20 per share, which equates to a $8.99 million pre-money valuation; and investors who participate in the offering after April 21, 2023 will invest at a purchase price of $1.50 per share, which equates to a $11.25 million pre-money valuation.
According to the U.S. Center for Disease Control, 20% of adults in the U.S. will experience chronic aches and pain at some point in their lives.
But it doesn’t have to be this way.
At Eva Medtec, we recognize that poor circulation is a leading cause of aches and pains for millions of people worldwide, not just in the U.S.
While many may attribute their discomfort to muscle strain or arthritis, it's important to understand that our circulatory system plays a vital role in removing harmful toxins, excess fluids, bacteria, and viruses from our bodies.
When circulation is impaired, pain and discomfort can become even more pronounced.
Revolutionizing Pain Management with Scientifically-Backed Technology
At Eva Medtec, we understand the crucial role that our circulatory and lymphatic systems play in our overall health and well-being.
Our innovative technology is based on decades of scientific research that has shown the interconnectedness of these systems, particularly in defending the body against infections and maintaining proper fluid balance. In extreme cases such as lymphedema and surgical recovery, doctors have recommended lymphatic massage, which has created an $8.15 billion market.
Eva Medtec's patented, FDA-cleared device - The Neuroglide - automates the lymphatic massage process, revolutionizing pain management for millions of daily sufferers from the comfort of their own home, without the need for a certified practitioner.
Neuroglide uses a precise and calibrated pressure profile to remove cellular waste associated with pain and inflammatory circulatory conditions, designed to speed up healing and improve quality of life.
Our affordable and convenient device incorporates proprietary therapy programs with customized materials designed to relax and relieve pain.
Engineered To Help Your Body Help Itself
Neuroglide’s benefits may include:
- Pain relief
- Lymph drainage
- Immune system stimulation
- Recovery and relaxation
"I credit Neuroglide with being able to recover in time for my race."
"I was impressed with how it replicated the Manual Lymph Drainage."
Frequently asked questions
An important contributor to the problem lies with the nature of the stress response itself. Our stress response evolved very early in our evolutionary history to help us deal with external challenges that demand physical action. But humans also respond to stressors that are purely psychological in origin, that aren’t attached to any imminent physical threat or challenge.
Worse, psychological stressors can persist indefinitely, with no opportunity for resolution or closure. Consider our seemingly bottomless capacity to worry about our relationships, money, our work life, our status in social groups, the upsetting news of the day, and so on. This is at least part of the answer to the question of why human beings are so vulnerable to chronic stress. Modern life provides a steady supply of psychological stressors, and our stress response is constantly being triggered. Our brains interpret these stressors as threats to our survival, and activate a “fight or flight” response that may have been adaptive in our evolutionary history, but is no longer adaptive when it persists.
This is why it’s so important to develop a therapeutic routine that gives us regular opportunities to disconnect from daily stressors and give our bodies a chance to rest, relax and recover.
There are at least two neurophysiological mechanisms that contribute to Neuroglide’s relaxation effects:
– Neuroglide therapy can trigger the “rest and digest” relaxation response. The soothing action of waves of gentle pressure beneath your skin stimulates your parasympathetic nervous system, which helps the body transition from a stressed “fight or flight” state to a relaxed “rest and digest” state.
– Neuroglide therapy can trigger the “affective touch” response. “Affective touch” is touch that is experienced as pleasurable and soothing.
Over the past 15 years, we have learned that there are sensory nerve fibers in our body that only respond to slow, gentle stroking of the skin. The brain interprets these touch signals as a sign that you are in an environment of safety, security, and belonging.
These kinds of social signals have therapeutic benefits that include deep relaxation and improved immune response.
Participants used a wearable device to monitor standard physiological measures of healthy stress response, relaxation and sleep quality, including:
– RHR: resting heart rate HRV—heart rate variability REM sleep Deep sleep Light sleep RECOVERY—calculated as RHR + HRV + SleepRHR—resting heart rate
– HRV: heart rate variability
– REM sleep
– Deep sleep
– Light sleep
– RECOVERY: calculated as RHR + HRV + Sleep
During the test period, the participants first used the device for seven days to set a baseline reading, then they used the Neuroglide Back/Neck Pad for 30 minutes prior to their regular sleep period.
Results of this study revealed a general improvement in RECOVERY (+14.6%), with a general increase in HRV as well as Deep and REM sleep overall.
The pilot study supports our working hypothesis that using the Neuroglide Back/Neck Pad may increase a person’s parasympathetic response, which is known to promote relaxation that can lead to improved sleep and/or recovery.
Studies like these highlight the exciting potential of Neuroglide therapy stimulating our body’s natural relaxation, pain relief and recovery systems.
success to date
Join us in our mission to revolutionize pain management!
- $130,533.50 raised on StartEngine
- FDA Clearance for Pain and Circulation
- Two US Patents issued
- Two more US patents-pending
- 85+ Investors
“Neuroglide’s a convenient way for me to manage my pain.”
Neuroglide’s $88B Total Addressable Market (TAM) (back and neck pain) is our total market demand for the Neuroglide in the US. The $9B Serviceable Available Market (SAM) segment of our TAM targeted by Neuroglide is within our geographical reach. Neuroglide’s $40M Serviceable Obtainable Market is the portion of SAM that we can capture.
We plan to continue distributing our Back/Neck Pad, and potential future add-on therapy attachments pending FDA clearance: Lumbar Pad, Calf-Foot Wrap, Knee Wrap, and Scalp Wrap. These attachments would work with the same Controller Unit.
Use of Proceeds
If the offering's maximum amount of $487,500 is raised:
|Use||Value||% of Proceeds|
|Sales and Marketing||$123,613||25.4%|
|New Product Development||$70,000||14.4%|
This is an offering of Common Stock, under registration exemption 4(a)(6), in Eva Medtec, Inc., doing business as Neuroglide. This offering must raise at least $10,000 by June 30, 2023 at 9:59pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neuroglide may issue additional securities to raise up to $487,500, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Neuroglide’s official name is Eva Medtec, Inc., so that’s the name that appears in the statements below.
These financial statements have been reviewed by an independent Certified Public Accountant.
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
- May 8, 2023Meet Our New Eva Medtec Medical Director!
Meet Our New Eva Medtec Medical Director!New Medical Director Announcement.pdf
- May 1, 2023Why Neuroglide plays an important part in...
Why Neuroglide plays an important part in solving the challenges of treating chronic neck and back pain!Neuroglide's Imprtance of Treating Chrinic Neck & Back Pain.pdf
- Apr 27, 2023Meet the Founder of Eva Medtec!
Meet the Founder of Eva Medtec!Update Founder Bio.pdf
- Apr 27, 2023
- Apr 24, 2023Learn more about Eva Medtec’s pilot sleep...
Learn more about Eva Medtec’s pilot sleep study.
The results of this study revealed an improvement in recovery (+14.6% for test period as a group), with an increase in HRV as well as Deep and REM sleep overall. This study indicates the Neuroglide system increases a person’s parasympathetic (rest and digest) response and may help promote relaxation that can lead to improved sleep and/or recovery.Eva Medtec Sleep Study.pdf
- Apr 21, 2023
- Apr 19, 2023Welcome to Eva Medtec’s Investment...
Welcome to Eva Medtec’s Investment Offering!!!
Our goal is to change the way physicians treat pain at-home and improve circulation. Patients and clinics are purchasing the Neuroglide to use with their hands-on Manual Lymphatic Drainage Therapy.
Eva Medtec has raised $3,900,000 to date from 88 investors. We look forward to your investment and your joining the Eva Medtec team!NetCapital Updates 4.19.2023.pdf
- Apr 14, 2023Primary offering of $1.50shares at
- Apr 14, 2023
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email email@example.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.